Back to Newsroom

Symic Bio Announces Results from the Phase 1/2 SHIELD Trial of SB-030 in Peripheral Vascular Disease

SAN​ ​FRANCISCO,​ ​Nov.​ ​1,​ ​2017​ – Symic Bio, a biopharmaceutical company developing novel matrix-targeting biotherapeutics, today announced results from the Phase 1/2 SHIELD trial evaluating
SB-030, a locally administered therapeutic, in patients with peripheral vascular disease undergoing angioplasty. In this first-in-human, prospective, randomized, single-blind controlled study of 67 patients, SB-030 demonstrated a positive safety profile, with no clinically meaningful difference observed in adverse events between treatment and control groups.